Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings
Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/
For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports.
The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion.
“Regulations change so often that it can be challenging for an institution to stay up-to-date,” said Nicolas Degruson, Director-Product Management. “Preparing and maintaining all the required information is resource-intensive and firms sometimes rely on multiple vendors to handle different aspects of the process. Moody’s Analytics offers a single, integrated solution that blends our regulatory expertise, deep understanding of risk, and award-winning technology.”
The next generation of our regulatory reporting software is now available. It can be implemented as software-as-a-service, allowing Moody’s Analytics to take care of the hosting, infrastructure, and software administration, in addition to delivering regulatory updates.
“Now in their 17th year, the Waters Rankings recognize the leading technologies, services, and providers operating across the capital markets," said Victor Anderson, Global Content Director of WatersTechnology. “What sets these rankings apart from others in the industry is that they are determined solely by our readers, based on their real-world experiences with different providers and solutions.”
This win adds to our growing list of awards and industry accolades.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE:MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
Moody’s Analytics Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Walgreens Boots Alliance and McKesson to Create German Wholesale Joint Venture12.12.2019 09:00:00 CET | Press release
Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today signed an agreement to create a joint venture that will combine their respective pharmaceutical wholesale businesses in Germany, Alliance Healthcare Deutschland and GEHE Pharma Handel. WBA will have a 70% controlling equity interest in the joint venture and McKesson will have a 30% ownership interest. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005230/en/ The new joint venture is expected to enhance the ability to compete and deliver high customer satisfaction through new services and operational excellence, ultimately advancing patient-centric solutions. In addition, the combined business will deliver efficient distribution solutions, and drive greater economies of scale, stimulating the competitiveness of the German pharmaceutical wholesale market. The transaction does not include any other WBA or McKesson businesses outside of the G
Indirect Tax Expert Peter Boerhof Joins Vertex12.12.2019 08:30:00 CET | Press release
Vertex, Inc., a leading provider of tax technology solutions, announced that Peter Boerhof has joined as VAT director in Europe. Boerhof joins Vertex from AkzoNobel where he was responsible for leading the global indirect tax function. He has extensive experience in international transactions, business restructuring, merger and acquisition, tax process optimization and tax automation. Unique in the tax technology industry, Vertex's Chief Tax Office (CTO) provides insight regarding the impact of tax regulations, policy, enforcement and emerging technology trends on global tax department operations. The Vertex CTO group consists of former tax executives from various Fortune 500 multinationals, who bring their in-house tax and industry expertise to Vertex's solution development, services and customer interactions. “We welcome Peter, who has extensive experience in global tax operations, including customs, VAT and relationship management with international tax administrations,” stated Vert
Kioxia Develops New 3D Semicircular Flash Memory Cell Structure “Twin BiCS FLASH”12.12.2019 07:37:00 CET | Press release
Kioxia Corporation today announced the development of the world’s first three-dimensional (3D) semicircular split-gate flash memory cell structure “Twin BiCS FLASH” using specially designed semicircular Floating Gate (FG) cells. Twin BiCS FLASH achieves superior program slope and a larger program/erase window at a much smaller cell size compared to conventional circular Charge Trap (CT) cells. These attributes make this new cell design a promising candidate to surpass four bits per cell (QLC) for significantly higher memory density and fewer stacking layers. This technology was announced at the IEEE International Electron Devices Meeting (IEDM) held in San Francisco, CA on December 11th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191211006038/en/ Fabricated semicircular FG cells (a) Cross-sectional view (b) Plane view (Graphic: Business Wire) 3D flash memory technology has achieved high bit density with low cost per b
BIOCORP and SANOFI Announce a Partnership to Fit SoloStar Insulin Pens With Mallya Technology Worldwide12.12.2019 06:30:00 CET | Press release
Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a worldwide partnership agreement with SANOFI for the use of Mallya technology, a connected device for insulin pens. This long-term agreement is the first decision resulting from exclusive negotiations initiated in July 2019. SANOFI and BIOCORP are thus fulfilling today their ambition to enter into a long-term partnership in the diabetes area. The agreement covers two main points: - Sanofi acquires the rights to a non-exclusive distribution of Mallya in its current version worldwide, starting in 2020. - BIOCORP is committed to develop a specific and exclusive version of Mallya for SoloStar, SANOFI's insulin pen. As a result of the agreement, Sanofi is to pay BIOCORP a further €2 million upon signature of the contract (last July, BIOCORP received a first pa
IFF Declares Dividend for Fourth Quarter 201911.12.2019 21:15:00 CET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy11.12.2019 21:05:00 CET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need